Novel therapy can improve the prognosis of relapsed/refractory acute myeloid leukemia

  • Post author:
  • Post category:uncategorized

Relapsed/refractory acute myeloid leukemia (AML), a so-called blood cancer, has an extremely poor prognosis because of resistance to anti-cancer drugs and frailty of the patient’s organ functions.